Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ASPH | Q12797 | 1/20 | 0.31 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12527639 | 0.78 | HTT (0.53) | HTTAPLNRCA2 | |
| SCHEMBL4062783 | 0.78 | HTT (0.44) | HTTCA2KDM4E | |
| SCHEMBL1396182 | 0.78 | APLNR (0.46) | APLNRAGBL2KDM4E | |
| SCHEMBL15331879 | 0.77 | HTT (0.42) | HTTCA2F2 | |
| SCHEMBL13771963 | 0.75 | HTT (0.46) | HTTCA2KDM4E | |
| SCHEMBL77616 | 0.75 | HTT (0.48) | HTTCA2F2KDM4E | |
| SCHEMBL4072658 | 0.74 | HTT (0.40) | HTTCA2 | |
| SCHEMBL12986732 | 0.74 | RAB9A (0.40) | APLNRAGBL2CA2 | |
| SCHEMBL28446989 | 0.74 | LMNA (0.39) | APLNRAGBL2MAOB | |
| SCHEMBL13765816 | 0.74 | HTT (0.44) | HTTAGBL2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4479054-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Nico Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| EP-4330236-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Denali Therapeutics Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| EP-4247376-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Denali Therapeutics Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| WO-2023158708-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| CN-116507608-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2022232632-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022109268-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NLRP3, NLRP1, NOD1 | HTT 3966/4885APLNR 1782/4885AGBL2 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.